• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

UMN researchers provide molecular portraits of a new cancer drug target

Bioengineer by Bioengineer
December 19, 2016
in Science News
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Unprecedented images of cancer genome-mutating enzymes acting on DNA provide vital clues into how the enzymes work to promote tumor evolution and drive poor disease outcomes. These images, revealed by University of Minnesota researchers, provide the first ever high-resolution pictures of molecular complexes formed between DNA and the human APOBEC3A and APOBEC3B enzymes.

The research is published today online in Nature Structural and Molecular Biology.

The DNA mutating enzymes called APOBECs are a major source of mutation in breast, lung, cervical, head/neck and many other cancer types.

"These enzymes normally function to protect us from viral infections," said Reuben Harris, Ph.D., investigator of the Howard Hughes Medical Institute and professor of Biochemistry, Molecular Biology, and Biophysics, member of the Masonic Cancer Center, and associate director of the Institute of Molecular Virology, University of Minnesota. "However, these enzymes can become misregulated in cancer cells and cause mutations in our own genomic DNA. These mutations fuel tumor evolution and promote poor clinical outcomes such as drug resistance and metastasis."

With an imaging technique called x-ray crystallography, which uses a high energy x-ray beam to visualize the atomic details of molecules, researchers were able to see an unexpected mode of DNA binding activity. A unique U-shaped DNA conformation and defined pockets for the target cytosine and the adjacent thymine base explains the specific mutation signature left behind by the enzyme interacting with tumor DNA.

"Our crystal structures and corroborating biochemical experiments show how APOBEC3A and APOBEC3B engage DNA substrates," said Hideki Aihara, Ph.D., associate professor in the department of Biochemistry, Molecular Biology and Biophysics and member of the Institute of Molecular Virology and the Masonic Cancer Center at the University of Minnesota. "These structures show an unexpected mode of DNA engagement with a sharply bent DNA strand and flipped-out nucleotides. Our findings were surprising, but actually make a lot of sense and explain many previous observations about this family of proteins."

The DNA-binding mechanism suggests ways to block enzyme activity in cancer, which could slow the rate at which tumors evolve. Inhibiting APOBEC activity could make current anti-cancer therapies more effective.

Work continues to take and analyze additional portraits of these enzymes with different DNA substrates and to devise strategies for enzyme inhibition.

Funding for this work is provided by grants from the National Institutes of Health (R01-GM118000, R35-GM118047, R01-GM110129, R21-CA206309, DP2-OD007237, P41-GM103426), the National Science Foundation (CHE060073N), the Prospect Creek Foundation and the Masonic Cancer Center, University of Minnesota. Harris is the Margaret Harvey Schering Land Grant Chair for Cancer Research at the University of Minnesota, and an Investigator of the Howard Hughes Medical Institute.

###

College of Biological Sciences faculty conduct research in all areas of biology from molecules to ecosystems with applications in medicine, environment, and biotechnology. The college offers seven undergraduate majors and five graduate programs. Our highly competitive undergraduate program attracts some of the brightest students at the University of Minnesota. Visit cbs.umn.edub to learn more.

Masonic Cancer Center, University of Minnesota is a Comprehensive Cancer Center designated by the National Cancer Institute. For more than 25 years, researchers, educators, and care providers have worked to discover the causes, prevention, detection, and treatment of cancer and cancer-related disease. Learn more about the Masonic Cancer Center at cancer.umn.edu.

The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school's 3,370 faculty and affiliate physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $177 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit http://www.med.umn.edu to learn more.

Media Contact

Stephanie Xenos
[email protected]
612-624-8723
@UMNews

http://www.umn.edu

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Microbiome Cell-Free RNA Differentiates Colorectal Cancer

July 8, 2025
blank

Evolving Deaminase Hotspots for Precise Cytosine Editing

July 7, 2025

HIV-1 Nuclear Entry Hinges on Capsid and Pore

July 7, 2025

Soil Dryness: Timing and Impact on Photosynthesis

July 7, 2025
Please login to join discussion

POPULAR NEWS

  • Zheng-Rong Lu

    Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    75 shares
    Share 30 Tweet 19
  • Enhancing Broiler Growth: Mannanase Boosts Performance with Reduced Soy and Energy

    72 shares
    Share 29 Tweet 18
  • AI Achieves Breakthrough in Drug Discovery by Tackling the True Complexity of Aging

    69 shares
    Share 28 Tweet 17
  • New Organic Photoredox Catalysis System Boosts Efficiency, Drawing Inspiration from Photosynthesis

    54 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbiome Cell-Free RNA Differentiates Colorectal Cancer

Evolving Deaminase Hotspots for Precise Cytosine Editing

HIV-1 Nuclear Entry Hinges on Capsid and Pore

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.